Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oncolytics Biotech Inc.
Biotech company issued Canadian patent for cellular proliferative disorders
November 4th, 2005
Oncolytics Biotech Inc. (ONC, ONCY) announced that it has been granted Canadian Patent 2,428,206 entitled "Methods for the treatment of cellular proliferative disorders." The claims describe methods of treating various types of cellular proliferative disorders including neurofibromatosis and neoplasms (cancers) by the administration of various strains of the reovirus. "The claims in Oncolytics' second Canadian patent provide broad coverage for the use of reovirus in treating cellular proliferative disorders including cancers," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "This patent complements existing intellectual property...
Source: Biotech Law Weekly (2005-11-04)
|
